A randomised placebo controlled trial of VSL#3^® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease.

ABSTRACT:

Background

Non-alcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular risk irrespective of conventional risk factors. The role of gut-liver interaction is implicated in its development. We investigated the effects of VSL#3^® probiotic supplementation on biomarkers of cardiovascular risk and liver injury in patients with NAFLD.

Methods

A randomised, double-blinded, placebo-controlled, proof-of-concept study was undertaken. Patients with NAFLD were randomly allocated to take 2 sachets VSL#3^® probiotic or placebo twice daily for 10 weeks. Measurements of endothelial function (digital photoplethysmography, sVCAM-1 and cGMP), oxidative stress (glutathione ratio and LHP), inflammation (hsCRP), insulin resistance (HOMA-IR) and liver i

SUBMITTER: Chong PL 

PROVIDER: S-EPMC8015038 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature